Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda

CONCLUSIONS: The Ad26.ZEBOV booster is safe and highly immunogenic in HIV+ adults with well-controlled infection. The Ad26.ZEBOV, MVA-BN-Filo regimen can generate long-term immune memory persisting for at least 4·5 years, resulting in a robust anamnestic response.TRIAL REGISTRATION: Pan African Clinical Trial Registry (PACTR202102747294430).CLINICALTRIALS: gov (NCT05064956).PMID:37981473 | DOI:10.1016/j.vaccine.2023.10.055

Source: Vaccine - November 19, 2023 Category: Allergy & Immunology Authors: Edward Man-Lik Choi Ggayi Abu-Baker Mustapher Gloria Omosa-Manyonyi Julie Foster Zacchaeus Anywaine Michael Musila Mutua Philip Ayieko Tobias Vudriko Irene Ann Mwangi Yusupha Njie Kakande Ayoub Moses Mundia Muriuki Kambale Kasonia Nicholas Edward Connor N Source Type: research